Five Prime Therapeutics (FPRX) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Five Prime Therapeutics (FPRX) Tops Q2 EPS by 7c
August 5, 2016 9:51 AM EDT
Jefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $60.00 (from $41.00) following Q2 results.
Yang commented, "Narrower 2Q net loss on higher revenue; estimated YE16 cash of ~$400M should fund operations into... More
August 5, 2016 8:16 AM EDT
Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $58.00 (from $45.00) following Q2 updated with the pipeline on track.
Schmidt commented, "We updating our estimates to reflect 2Q16 financial results and are maintaining our OP rating on FPRX shares despite the recent... More
